Skip to Content

ASCO GI 2024: ctDNA Status Post-Surgery is a Significant Predictor of Survival in Patients Following Surgery for Colorectal Cancer

A new study has brought to light the transformative potential of circulating tumor DNA (ctDNA) in the post-surgical management of colorectal cancer. The research, which will be presented at the 2024 ASCO GI, delves into the use of ctDNA for monitoring molecular residual disease (MRD) in patients following colorectal cancer surgery.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top